$BPTH
BIO-PATH HOLDINGS, INC.

2021 Q4 Form 10-K Financial Statement

#000155837022003298 Filed on March 10, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.209M $4.533M $1.010M
YoY Change 19.7% 4.69% -9.82%
% of Gross Profit
Research & Development $2.908M $5.910M $1.540M
YoY Change 88.83% -10.16% 19.38%
% of Gross Profit
Depreciation & Amortization $20.00K $100.0K $20.00K
YoY Change 0.0% 0.0% 100.0%
% of Gross Profit
Operating Expenses $4.117M $10.44M $2.550M
YoY Change 61.45% -4.26% 5.81%
Operating Profit -$10.44M
YoY Change -4.26%
Interest Expense $1.000K $3.000K $0.00
YoY Change -90.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $3.000K
YoY Change -88.46%
Pretax Income -$4.116M -$10.44M -$2.550M
YoY Change 61.41% -4.06% 6.69%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.116M -$10.40M -$2.550M
YoY Change 61.41% -4.59% 6.69%
Net Earnings / Revenue
Basic Earnings Per Share -$1.55
Diluted Earnings Per Share -$574.4K -$1.55 -$591.6K
COMMON SHARES
Basic Shares Outstanding 7.160M 6.725M
Diluted Shares Outstanding 6.725M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.77M $23.77M $13.76M
YoY Change 72.78% 72.78% -32.65%
Cash & Equivalents $23.77M $13.76M
Short-Term Investments
Other Short-Term Assets $1.843M $2.366M $928.0K
YoY Change 98.6% 7.55% -40.89%
Inventory
Prepaid Expenses $523.0K $1.273M
Receivables
Other Receivables
Total Short-Term Assets $26.14M $26.14M $15.96M
YoY Change 63.83% 63.78% -27.44%
LONG-TERM ASSETS
Property, Plant & Equipment $225.0K $428.0K $231.0K
YoY Change -2.6% -17.69% -65.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $428.0K $428.0K $519.0K
YoY Change -17.53% -17.69% -22.54%
TOTAL ASSETS
Total Short-Term Assets $26.14M $26.14M $15.96M
Total Long-Term Assets $428.0K $428.0K $519.0K
Total Assets $26.57M $26.57M $16.48M
YoY Change 61.26% 61.21% -27.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $100.0K $6.000K $100.0K
YoY Change 0.0% -94.0% -79.59%
Accrued Expenses $800.0K $852.0K $1.000M
YoY Change -20.0% -20.37% 31.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $958.0K $958.0K $1.169M
YoY Change -18.05% -18.12% -5.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $153.0K $153.0K $240.0K
YoY Change -36.25% -36.25% -27.27%
Total Long-Term Liabilities $153.0K $153.0K $240.0K
YoY Change -36.25% -36.25% -27.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $958.0K $958.0K $1.169M
Total Long-Term Liabilities $153.0K $153.0K $240.0K
Total Liabilities $1.111M $1.111M $1.405M
YoY Change -20.93% -21.21% -10.51%
SHAREHOLDERS EQUITY
Retained Earnings -$77.66M -$67.22M
YoY Change 15.53%
Common Stock $7.000K $5.000K
YoY Change 40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.46M $25.46M $15.07M
YoY Change
Total Liabilities & Shareholders Equity $26.57M $26.57M $16.48M
YoY Change 61.26% 61.21% -27.29%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$4.116M -$10.40M -$2.550M
YoY Change 61.41% -4.59% 6.69%
Depreciation, Depletion And Amortization $20.00K $100.0K $20.00K
YoY Change 0.0% 0.0% 100.0%
Cash From Operating Activities -$2.801M -$9.917M -$2.590M
YoY Change 8.15% -9.52% 15.63%
INVESTING ACTIVITIES
Capital Expenditures -$23.00K $70.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$23.00K -$70.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $15.85M
YoY Change 269.53%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.000K 20.01M 4.290M
YoY Change -100.07% 366.45% -41.15%
NET CHANGE
Cash From Operating Activities -2.801M -9.917M -2.590M
Cash From Investing Activities -23.00K -70.00K
Cash From Financing Activities -3.000K 20.01M 4.290M
Net Change In Cash -2.827M 10.02M 1.700M
YoY Change -266.29% -250.19% -66.34%
FREE CASH FLOW
Cash From Operating Activities -$2.801M -$9.917M -$2.590M
Capital Expenditures -$23.00K $70.00K
Free Cash Flow -$2.778M -$9.987M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6725000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3847000
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001133818
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4542000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7160000
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.83
CY2019Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021 us-gaap Operating Loss Carryforwards Expiration Date
OperatingLossCarryforwardsExpirationDate
2026-12-31
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-36333
CY2021 dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
CY2021 dei City Area Code
CityAreaCode
832
CY2021 dei Local Phone Number
LocalPhoneNumber
742-1357
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
BPTH
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7160164
CY2021Q2 dei Entity Public Float
EntityPublicFloat
46197553.90
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Houston, Texas
CY2021Q4 us-gaap Cash
Cash
23774000
CY2020Q4 us-gaap Cash
Cash
13755000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
523000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1273000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1843000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
928000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
26140000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
15956000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1099000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1029000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
874000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
798000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
225000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
231000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
203000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
288000
CY2021Q4 us-gaap Assets
Assets
26568000
CY2020Q4 us-gaap Assets
Assets
16475000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
106000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
100000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
770000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
975000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
94000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
958000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1169000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
153000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
236000
CY2021Q4 us-gaap Liabilities
Liabilities
1111000
CY2020Q4 us-gaap Liabilities
Liabilities
1405000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7160000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4542000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103111000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
82286000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77661000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67221000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25457000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15070000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26568000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16475000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5910000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6578000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4533000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4330000
CY2021 us-gaap Operating Expenses
OperatingExpenses
10443000
CY2020 us-gaap Operating Expenses
OperatingExpenses
10908000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-10443000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-10908000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10440000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10882000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.83
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6725000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3847000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10440000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10882000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
821000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
577000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
85000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
79000
CY2021 us-gaap Depreciation
Depreciation
76000
CY2020 us-gaap Depreciation
Depreciation
72000
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-750000
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
497000
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
915000
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
140000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-199000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-84000
CY2021 bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
95000
CY2020 bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
85000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9917000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10960000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
70000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15849000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4289000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4157000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20006000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4289000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10019000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6671000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13755000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20426000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23774000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13755000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
21086000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4289000
CY2020 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
577000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10882000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15070000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15070000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15849000
CY2021 bpth Stock Issue During Period Value Warrants Exercised
StockIssueDuringPeriodValueWarrantsExercised
4157000
CY2021 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
821000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10440000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25457000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk — </span>Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash. The Company maintains its cash balances with one major commercial bank, JPMorgan Chase Bank. The balances are insured by the Federal Deposit Insurance Corporation (the “FDIC”) up to $250,000. As a result, as of December 31, 2021, approximately $23.5 million of its cash balance was not covered by the FDIC. As of December 31, 2020, the Company had approximately $13.8 million in cash on-hand, of which approximately $13.5 million was not covered by the FDIC. To date, the Company has not incurred any losses on its cash balances.</p>
CY2020 us-gaap Depreciation
Depreciation
100000
CY2021 us-gaap Depreciation
Depreciation
100000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77700000
CY2021Q4 us-gaap Cash
Cash
23800000
CY2021Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
485908
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
274008
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates —</span> The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States (“U.S.”) requires management to make estimates and assumptions that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends as well as on various other assumptions that the Company believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from the Company’s estimates. These estimates include accrued clinical trial costs, stock-based compensation expense, valuation of warrants and valuation of deferred tax assets.</p>
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10400000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10900000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1300000
CY2021Q4 bpth Expected Advanced Payment To Be Expensed
ExpectedAdvancedPaymentToBeExpensed
500000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1099000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1029000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
874000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
798000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
225000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
231000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
800000
CY2021Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
400000
CY2021Q4 bpth Accrued Manufacturing Expense
AccruedManufacturingExpense
100000
CY2021Q4 bpth Accrued Legal And Patent Fees
AccruedLegalAndPatentFees
100000
CY2021Q4 bpth Accrued Manufacturing Expense
AccruedManufacturingExpense
100000
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1000000.0
CY2020Q4 bpth Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
400000
CY2020Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
400000
CY2020Q4 bpth Accrued Manufacturing Expense
AccruedManufacturingExpense
100000
CY2020Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12200000
CY2021 bpth Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
428907
CY2021 bpth Weighted Average Exercise Price
WeightedAverageExercisePrice
9.71
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4200000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.22
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.34
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0115
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0050
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.28
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.22
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
274000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.57
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3750000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
213000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.02
CY2021 bpth Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodContractualTerm
P9Y3M18D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
72.67
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
486000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.58
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7800000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
451000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
15.21
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
7114000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
178000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
28.09
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3412000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
68000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
68.56
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
211000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.01
CY2020 bpth Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodContractualTerm
P9Y4M24D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.19
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
28.67
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
274000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.57
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3750000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
238000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
22.66
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
66000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
63.95
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3070000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
800000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1400000
CY2021 bpth Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndUnvestedWeightedAverageRemainingContractualTerm
P2Y6M
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
600000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
430000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y6M
CY2021 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Option Outstanding Weighted Average Exercise Price Per Share
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionOutstandingWeightedAverageExercisePricePerShare
27.61
CY2021Q4 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionsExercisableNumberOfShares
430000
CY2021 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Weighted Average Exercise Price Per Share
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePricePerShare
27.61
CY2021Q4 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
2600000
CY2014Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2019Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2016Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2021 bpth Operating Lease Incremental Borrowing Rate Utilized
OperatingLeaseIncrementalBorrowingRateUtilized
0.080
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
203000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
288000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
94000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
153000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
236000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
235000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
330000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
117000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
115000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
11000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
6000
CY2021 us-gaap Lease Cost
LeaseCost
128000
CY2020 us-gaap Lease Cost
LeaseCost
121000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
98000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
89000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
76000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
263000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
28000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
235000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2021 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Match First3 Of Base Salary
DefinedContributionPlanEmployerMatchingContributionPercentOfMatchFirst3OfBaseSalary
1
CY2021 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Employees Gross Pay Tranche One
DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayTrancheOne
0.03
CY2021 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Match On Next2 Of Base Salary
DefinedContributionPlanEmployerMatchingContributionPercentOfMatchOnNext2OfBaseSalary
0.50
CY2021 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Employees Gross Pay Tranche Two
DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayTrancheTwo
0.02
CY2021Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
39000
CY2020Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
30000
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
71300000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
35800000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
35500000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2600000
CY2021 bpth Valuation Allowance As Percent Of Deferred Tax Assets
ValuationAllowanceAsPercentOfDeferredTaxAssets
1
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
19000000.0
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16400000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
63000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
53000
CY2021Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
26000
CY2020Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
24000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14975000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12876000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3353000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2902000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
572000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
472000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4000
CY2021Q4 bpth Deferred Tax Right Of Use Liability
DeferredTaxRightOfUseLiability
-49000
CY2020Q4 bpth Deferred Tax Right Of Use Liability
DeferredTaxRightOfUseLiability
-69000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
43000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
55000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19085000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16455000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19042000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16395000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
43000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
60000
CY2021Q4 bpth Deferred Tax Right Of Use Asset
DeferredTaxRightOfUseAsset
-43000
CY2020Q4 bpth Deferred Tax Right Of Use Asset
DeferredTaxRightOfUseAsset
-60000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10440000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10882000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2193000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2285000
CY2021 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
73000
CY2020 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
50000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
451000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
832000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2648000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2990000
CY2021 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-77000
CY2020 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
77000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001558370-22-003298-index-headers.html Edgar Link pending
0001558370-22-003298-index.html Edgar Link pending
0001558370-22-003298.txt Edgar Link pending
0001558370-22-003298-xbrl.zip Edgar Link pending
bpth-20211231.xsd Edgar Link pending
bpth-20211231x10k.htm Edgar Link pending
bpth-20211231x10k001.jpg Edgar Link pending
bpth-20211231x10k002.jpg Edgar Link pending
bpth-20211231x10k003.jpg Edgar Link pending
bpth-20211231x10k004.jpg Edgar Link pending
bpth-20211231x10k005.jpg Edgar Link pending
bpth-20211231x10k_htm.xml Edgar Link completed
bpth-20211231xex23d1.htm Edgar Link pending
bpth-20211231xex31.htm Edgar Link pending
bpth-20211231xex32.htm Edgar Link pending
bpth-20211231_cal.xml Edgar Link unprocessable
bpth-20211231_def.xml Edgar Link unprocessable
bpth-20211231_lab.xml Edgar Link unprocessable
bpth-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending